Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.850
-0.270 (-6.55%)
At close: Feb 13, 2026, 4:00 PM EST
4.000
+0.150 (3.90%)
After-hours: Feb 13, 2026, 7:23 PM EST

SAB Biotherapeutics Revenue

SAB Biotherapeutics had revenue of $114.70K in the twelve months ending September 30, 2025, down -92.42% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.

Revenue (ttm)
$114.70K
Revenue Growth
-92.42%
P/S Ratio
1,597.99
Revenue / Employee
$1,821
Employees
63
Market Cap
183.29M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20241.32M-916.58K-40.94%
Dec 31, 20232.24M-21.67M-90.63%
Dec 31, 202223.90M-36.97M-60.73%
Dec 31, 202160.88M5.64M10.21%
Dec 31, 202055.24M51.80M1,504.91%
Dec 31, 20193.44M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Voyager Therapeutics31.32M
C4 Therapeutics30.11M
Sol-Gel Technologies18.97M
Prelude Therapeutics10.50M
Tonix Pharmaceuticals Holding10.30M
Ovid Therapeutics6.61M
Revenue Rankings

SABS News

More News